Telligent Fund LP Has $7.09 Million Stock Position in Eli Lilly and Company $LLY

Telligent Fund LP lessened its position in shares of Eli Lilly and Company (NYSE:LLY) by 8.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 6,600 shares of the company’s stock after selling 600 shares during the period. Eli Lilly and Company makes up approximately 7.9% of Telligent Fund LP’s investment portfolio, making the stock its 4th largest position. Telligent Fund LP’s holdings in Eli Lilly and Company were worth $7,093,000 at the end of the most recent reporting period.

A number of other institutional investors also recently made changes to their positions in the company. Vanguard Group Inc. boosted its holdings in shares of Eli Lilly and Company by 1.2% during the fourth quarter. Vanguard Group Inc. now owns 81,965,974 shares of the company’s stock worth $88,087,193,000 after acquiring an additional 1,006,885 shares during the period. State Street Corp boosted its position in shares of Eli Lilly and Company by 0.6% in the third quarter. State Street Corp now owns 34,726,558 shares of the company’s stock valued at $26,496,364,000 after acquiring an additional 219,590 shares during the period. Capital Research Global Investors boosted its position in shares of Eli Lilly and Company by 20.9% in the third quarter. Capital Research Global Investors now owns 25,088,371 shares of the company’s stock valued at $19,141,787,000 after acquiring an additional 4,332,008 shares during the period. Wellington Management Group LLP boosted its position in shares of Eli Lilly and Company by 4.1% in the third quarter. Wellington Management Group LLP now owns 14,563,780 shares of the company’s stock valued at $11,112,164,000 after acquiring an additional 574,229 shares during the period. Finally, Capital International Investors boosted its position in shares of Eli Lilly and Company by 6.1% in the third quarter. Capital International Investors now owns 10,001,509 shares of the company’s stock valued at $7,628,447,000 after acquiring an additional 579,381 shares during the period. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: CVS Caremark is restoring coverage for Zepbound and adding Foundayo to drug plans, and Lilly said all three of the largest U.S. pharmacy benefit managers now cover its full obesity portfolio, improving commercial access and revenue potential. Reuters: CVS brings back coverage for Lilly’s obesity drug Zepbound
• Positive Sentiment: Lilly announced three vaccine acquisitions worth up to about $3.8 billion, signaling a broader growth strategy beyond obesity and diabetes and potentially opening a new long-term market opportunity. Reuters coverage of Lilly vaccine acquisitions
• Positive Sentiment: New clinical data presented for Foundayo, Mounjaro, and retatrutide highlighted strong efficacy in obesity and diabetes, reinforcing investor confidence in Lilly’s cardiometabolic pipeline. PR Newswire: Lilly to present new data…
• Positive Sentiment: Several analysts reiterated bullish views and higher price targets, including a BofA target increase, which supports the stock’s momentum and valuation narrative. InsiderMonkey: Eli Lilly among safe stocks
• Neutral Sentiment: Lilly’s presentation at Bernstein and upcoming conference appearances are keeping investors focused on management commentary, but these events are more about confirming the existing growth story than creating a new catalyst. Seeking Alpha transcript
• Negative Sentiment: Some commentary argues Novo Nordisk may be a better short-term value, and Lilly’s rich valuation could limit upside if growth expectations slow. Motley Fool: Novo Nordisk Is A Better Buy Than Eli Lilly Right Now

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on LLY. UBS Group reissued a “buy” rating on shares of Eli Lilly and Company in a research report on Wednesday, March 18th. Truist Financial reissued a “buy” rating on shares of Eli Lilly and Company in a research report on Monday, February 23rd. Daiwa Securities Group boosted their price target on Eli Lilly and Company from $1,230.00 to $1,250.00 and gave the company a “buy” rating in a research note on Wednesday, February 18th. Berenberg Bank boosted their price target on Eli Lilly and Company from $950.00 to $1,050.00 and gave the company a “hold” rating in a research note on Thursday, February 19th. Finally, Loop Capital set a $1,200.00 price target on Eli Lilly and Company in a research note on Tuesday, February 10th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $1,227.00.

Eli Lilly and Company Stock Up 4.0%

NYSE LLY opened at $1,126.66 on Friday. The stock has a market capitalization of $1.06 trillion, a PE ratio of 40.02, a PEG ratio of 1.18 and a beta of 0.48. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,149.10. The business has a fifty day moving average price of $952.15 and a two-hundred day moving average price of $1,009.10.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, April 30th. The company reported $8.55 EPS for the quarter, topping analysts’ consensus estimates of $6.97 by $1.58. The firm had revenue of $19.80 billion during the quarter, compared to analysts’ expectations of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The business’s revenue for the quarter was up 55.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Equities analysts expect that Eli Lilly and Company will post 35.8 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th will be issued a $1.73 dividend. The ex-dividend date of this dividend is Friday, May 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. Eli Lilly and Company’s dividend payout ratio is 24.58%.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.